Drug Development for Rare Mitochondrial Disorders

Neurotherapeutics

Volumn 10, Issue 2, 2013, Pages 286-306

  Hurko, Orest ^a  

^a Clinical Translational Medicine   (United States)

Author keywords

Biomarkers; Clinical trials; Drugs; Food and drug administration; Mitochondrial; Rare diseases

Indexed keywords

ALPHA TOCOPHERYLQUINONE; ALPHA TOCOTRIENOL QUINONE; BIOLOGICAL MARKER; CARNITINE; IDEBENONE; UBIQUINONE;

DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG APPROVAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; RARE DISEASE; REVIEW;

EID: 84876195487     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0179-4     Document Type: Review

References (132)

1. Clinical Trials. gov: A service of the NIH. Available at: www. clinicaltrials. gov. Accessed September 4, 2012.
2. Stacpoole PW. Why are there no proven therapies for genetic mitochondrial diseases? Mitochondrion 2011; 11: 679-685.
3. Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4: CD004426.
4. Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010; 99: 246-255.
5. Mancuso M, Orsucci D, Filosto M, et al. Drugs and mitochondrial diseases: 40 queries and answers. Expert Opin Pharmacother 2012; 13: 527-543.
6. Suomalainen A. Therapy for mitochondrial disorders: little proof, high research activity, some promise. Semin Fetal Neonatal Med 2011; 16: 236-240.
7. Pandolfo M. Drug insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol 2008; 4: 86-96.
8. Determining if a Drug is FDA Approved. Available at www. fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm119742. htm. Accessed August 15, 2012.
9. Guidance for FDA Staff and Industry Marketed Unapproved Drugs - Compliance Policy Guide. Available at http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070290. pdf. Accessed September 4, 2012.
10. Dietary Supplement Health and Education Act (DSHEA). Available at www. fda. gov/food/dietarysupplements/default. htm/food/dietarysupplement. Accessed September 4, 2012.
11. Dietary Supplement Alerts and Safety Information website. Available at www. fda. gov/Food/DietarySupplements/Alerts/default. htm. Accessed September 4, 2012.
12. Hirano M, Garone C, Quinzii CM. CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders. Biochim Biophys Acta 2012; 1820: 625-631.
13. Quinzii CM, Hirano M. Primary and secondary CoQ(10) deficiencies in humans. Biofactors 2011; 37: 361-365.
14. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 2010; 16: 183-188.
15. Quinzii CM, López LC, Naini A, DiMauro S, Hirano M. Human CoQ10 deficiencies. Biofactors 2008; 32: 113-118.
16. Lamhonwah A-M, Olpin SE, Pollitt RJ, et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet 2002; 111: 271-284.
17. Schöls L, Zange J, Abele M, et al. M. J Neural Transm. L-carnitine and creatine in Friedreich's Ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 2005; 112: 789-796.
18. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679.
19. Kearney M, Orrell RW, Fahey M, et al. Antioxidants and other pharmacological treatments for Friedreich Ataxia. Cochrane Database Syst Rev 2012; 18; 4: CD007791.
20. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreichs Ataxia. Heart 2002; 87: 346-349.
21. Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich's Ataxia: neurological, cardiac, and biochemical monitoring. Neurology 2003; 60: 1679-1681.
22. Rustin P, Rötig A, Munnich A, et al. Heart hypertrophy and function are improved by idebenone in Friedreich's Ataxia. Free Radic Res 2002; 36: 467-469.
23. Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich Ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011; 161: 639-645.
24. Drinkard BE, Keyser RE, Paul SM, et al. Exercise capacity and idebenone intervention in children and adolescents with Friedreich Ataxia. Arch Phys Med Rehabil. 2010; 91: 1044-1050.
25. Health Canada summary basis of decision (SBD) for PRCATENA®. Available at http://www. hc-sc. gc. ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2009_catena_117672-eng. php.
26. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell 2012; 148: 1145-1159.
27. Ylikallio E, Suomalainen A. Mechanisms of mitochondrial diseases. Ann Med 2012; 44: 41-59.
28. Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes-many genes, common mechanisms. Neuromuscul Disord 2010; 20: 429-437.
29. Field MJ, Boat TF (eds) (2010) Rare diseases and orphan products: accelerating research and development. The National Academies Press, Washington, DC.
30. FDA Cellular & Gene Therapy. Available at: www. fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances /CellularandGeneTherapy/default. htm. Accessed September 3, 2012.
31. FDA Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). Available at: http://www. fda. gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm092705. pdf. Accessed September 4, 2012.
32. FDA Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events. Available at: www. fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072957. htm. Accessed September 3, 2012.
33. FDA Guidance for Industry: Human Somatic Cell Therapy and Gene Therapy. Available at: www. fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072987. htm Accessed September 3, 2012.
34. FDA References for the Regulatory Process for the Office of Cellular, Tissue and Gene Therapies. Available at: www. fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/ucm094338. htm. Accessed September 3, 2012.
35. Di Prospero NA, Sumner CJ, Penzak SR, et al. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich Ataxia. Arch Neurol 2007; 64: 803-808.
36. Schulz JB, Di Prospero NA, Fischbeck K. Clinical experience with high-dose idebenone in Friedreich Ataxia. J Neurol 2009; 256(Suppl. 1): 42-45.
37. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20: 1502-1509.
38. Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2011;(2): CD004760.
39. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134: 2677-2686.
40. Rudolph G, Dimitriadis K, Büchner B, et al. Effects of idebenone on color vision in patients with Leber Hereditary Optic Neuropathy. J Neuroophthalmol 2012 Dec 21 [Epub ahead of print].
41. Rosenfeld AE, Sadun AA. Treatments for Leber's hereditary optic neuropathy. Drugs Future 2010; 35: 129-133.
42. Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol 2012; 69: 331-338.
43. Shrader WD, Amagata A, Barnes A, et al. Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. Bioorg Med Chem Lett 2011; 21: 3693-3698.
44. Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease--genetically defined Leigh Syndrome. Mol Genet Metab 2012; 107: 383-388.
45. Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012; 105: 91-102.
46. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117: 1519-1531.
47. Stacpoole PW, DeGrauw TJ, Feigenbaum AS, et al. Design and implementation of the first randomized controlled trial of coenzyme Q(10) in children with primary mitochondrial diseases. Mitochondrion 2012; 12: 623-629.
48. Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme q10 in mitochondrial disorders. Neurology 2000; 55: 1748-1751.
49. Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants. Available at www. fda. gov/downloads/Drugs/.../Guidances/ucm153222. pdf. Accessed September 4, 2012.
50. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich Ataxia. Arch Neurol 2010; 67: 941-947.
51. Approved Risk Evaluation and Mitigation Strategies (REMS). Available at www. fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350. htm. Accessed September 4, 2012.
52. Wellman-Labadie O, Zhou Y. The U. S. Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 2009; 95: 216-228.
53. FDA Application Search Orphan Drug Designations and Approvals. Available at: www. accessdata. fda. gov/scripts/opdlisting/oopd/. Accessed September 3, 2012.
54. McKusick VA, Antonarakis SE, Francomano CA, et al. Online Mendelian Inheritance in Man: A catalog of human genes and genetic disorders. Available at: www. ncbi. nlm. nih. gov/omim. Accessed September 3, 2012.
55. FDA Guidance: Providing Evidence of Clinical Effectiveness for Human Drugs and & Biological Products. Available at: www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749. pdfv. Accessed September 3, 2012.
56. Federal Register/Vol. 62, No. 104 [Docket No. 97D-0188] International Conference on Harmonisation; Draft Guideline on General Considerations for Clinical Trials. Available at www. gpo. gov/fdsys/pkg/FR-1997-05-30/pdf/97-14139. pdf. Accessed September 4, 2012.
57. ICH Topic E 9 Statistical Principles for Clinical Trials. Available at www. emea. europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928. pdf. Accessed on September 4, 2012.
58. Pariser A. FDA regulation and review of small clinical trials. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4, 2010.
59. Mitsumoto J, Dorsey ER, Beck CA, et al. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009; 66: 184-190.
60. FDA News Release Biomarker Development and Clinical Trial Design Greatest Areas for Impact. Available at: www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108619. htm. Accessed September 3, 2012.
61. Hull K. Study designs for rare diseases. Available at: rarediseasesnetwork. epi. usf. edu/conference/documents/slides/HULL-StudyDesigninRareDiseases. pdf.
62. Institute of Medicine (2001) Small Clinical Trials: Issues and Challenges. National Academy Press, Washington, DC.
63. Coffey C. Methods of particular Interest to Small Clinical Trials (Part 1). Available at: videocast. nih. gov/Summary. asp?file=15639. Accessed September 4, 2012.
64. Bland JM, Altman DG. Analysis of continuous data from small samples. BMJ 2009; 339: 961-962.
65. Altman DG, Bland JM. Parametric vs. non-parametric methods for data analysis. BMJ 2009; 339: 170.
66. Berry DA Bayesian clinical trials. Nat Rev Drug Discov 2006; 5: 27-36.
67. Day S. The Science of Small Clinical Trials. Available at: small-trials. keenminds. org/presenters/SSCT_2011_01_Day. ppt. Accessed September 4, 2012.
68. Wittes J. Science of Small Clinical trials: Lecture 5 - Methods of particular Interest to Small Clinical Trials (Part 2). Available at: videocast. nih. gov/summary. asp?live=8496. Accessed September 3, 2012.
69. FDA Critical Path Opportunities Report 2006. Available at: www. fda. gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254. pdf. Accessed September 3, 2012.
70. FDA Draft Guidance for Industry: Qualification Process for Drug Development Tools. 2010. Available at: www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597. pdf. Accessed September 3, 2012.
71. Guidance for Industry E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions. Available at: http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM267449. pdf. Accessed September 4, 2012.
72. Hurko O. The uses of biomarkers in drug development. Ann NY Acad Sci 2009; 1180: 1-10.
73. Hurko O, Jones GK. Valuation of biomarkers. Nat Rev Drug Discov 2011; 10: 253-254.
74. Suomalainen A. Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011; 34: 277-282.
75. Quinzii CM, Garone C, Emmanuele V, et al. Tissue-specific oxidative stress and loss of mitochondria in CoQ-deficient Pdss2 mutant mice. FASEB J. 2013 Jan 3 [Epub ahead of print].
76. Eleff SM, Barker PB, Blackband SJ et al. Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine. Ann Neurol 1990; 27: 626-630.
77. Hurko O, Johns DR, Rutledge SL, et al. Heteroplasmy in chronic progressive external ophthalmoplegia: Clinical and molecular observations. Pediatr Res 1990; 28: 542-548.
78. Tyynismaa H, Carroll CJ, Raimundo N, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 2010; 19: 3948-3958.
79. Suomalainen A, Elo JM, Pietiläinen KH, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011; 10: 806-818.
80. Atkuri KR, Cowan TM, Kwan T, et al. Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci U S A 2009; 106: 3941-3945.
81. Blankenberg FG, Kinsman SL, Cohen BH, et al. Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease. Mol Genet Metab 2012; 107: 690-699.
82. Temple R. How FDA currently makes decisions on clinical studies. Clin Trials 2005; 2: 276-281.
83. Fast Track, Accelerated Approval and Priority Review Accelerating Availability of New Drugs for Patients with Serious Diseases. Available at http://www. fda. gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoImportantNewTherapies/ucm128291. htm. Accessed December 31, 2012.
84. CFR - Code of Federal Regulations Title 21, Chapter I, Subchapter D, Part 314, Subpart H. Available at: http://www. accessdata. fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?CFRPart=314&showFR=1&subpartNode=21: 5. 0. 1. 1. 4. 8. Accessed September 4, 2012.
85. CFR - Code of Federal Regulations Title 21, Chapter I, Subchapter F, Part 601, Subpart E. Available at: http://www. accessdata. fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?CFRPart=601&showFR=1&subpartNode=21: 7. 0. 1. 1. 2. 5. Accessed September 1, 2012.
86. FDA. Table of Pharmacogenomic Biomarkers in Drug Labels. Available at: http://www. fda. gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378. htm. Accessed September 4, 2012.
87. Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004; 1: 189-195.
88. Braun MM, Farag-El-Massah S, Xu K, et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Disc 2010; 9: 519-522.
89. Talele SS, Xu K, Pariser AR, et al. Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Pediatrics 2010; 126: 101-106.
90. 112th Congress, 2nd Session. Suspend the Rules and Pass the Bill, S. 3187, with an Amendment. Available at http://docs. house. gov/billsthisweek/20120618/BILLS-112s3187-SUS. pdf. Accessed January 7, 2013.
91. United States Government Accountability Office. New drug approval; FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints. GAO-09-866. 2009.
92. FDA Guidance for Industry: Special Protocol Assessment. Available at: http://www. fda. gov/downloads/Drugs/.../Guidances/ucm080571. pdf. Accessed September 4, 2012.
93. McCaughan M. RPM Report - "Breakthrough Therapy": New Pathway in FDASIA May Point The Way To Future Reforms. Available at http://www. focr. org/rpm-report-qbreakthrough-therapyq-new-pathway-in-fdasia-may-point-the-way-to-future-reforms. html, Accessed January 2, 2013.
94. Heemstra HE, Hubert GM Leufkens HGM, et al. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today 2011; 16: 73-80.
95. Blatt T, Littarru GP. Biochemical rationale and experimental data on the antiaging properties of CoQ(10) at skin level. Biofactors 2011; 37: 381-385.
96. Day M, Chandran P, Luo F, et al. Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography. Neuroscience 2011; 189: 299-304.
97. Galpern WR, Cudkowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion 2007; 7(Suppl,): S146-153.
98. Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med 2011; 51: 1014-1026.
99. von Bernhardi R, Eugenín J. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 2012; 16: 974-1031.
100. Su B, Wang X, Bonda D, et al. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease? Mol Neurobiol 2010; 41: 87-96.
101. Wadsworth TL, Bishop JA, Pappu AS, et al. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis 2008; 14: 225-234.
102. Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002; 61: 191-202.
103. Santos Corraliza E, Fuertes Martín A. Antiretroviral therapy and mitochondrial toxicity. Med Clin (Barc) 2007; 128: 311-316.
104. ter Hofstede HJ, Borm GF, Koopmans PP. Oral glucose loading for detection of mitochondrial toxicity during HAART in HIV-infected patients. Curr HIV Res 2007; 5: 389-393.
105. Reiss P, Casula M, de Ronde A, et al. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine + didanosine or zidovudine + zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med 2004; 5: 11-14.
106. Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol 1995; 90: 1-6.
107. Peters BS, Winer J, Landon DN, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med 1993; 86: 5-15.
108. Dai YL, Luk TH, Yiu KH, et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 2011; 216: 395-401.
109. Bonnefont JP, Bastin J, Laforêt P, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 2010; 88: 101-108.
110. Hicks D, Lampe AK, Laval SH, et al. Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Brain 2009; 132: 147-155.
111. Merlini L, Bernardi P. Therapy of collagen VI-related myopathies (Bethlem and Ullrich). Neurotherapeutics 2008; 5: 613-618.
112. Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 2003; 142: 62-66.
113. Meier T, Perlman SL, Rummey C, et al. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 2012; 259: 284-291.
114. Cooper JM, Korlipara LV, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008; 15: 1371-1379.
115. Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62: 621-626.
116. Tonon C, Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother 2008; 9: 2327-2337.
117. Myers L, Farmer JM, Wilson RB, et al. Antioxidant use in Friedreich ataxia. J Neurol Sci 2008; 267: 174-176.
118. Di Prospero NA, Baker A, Jeffries N, et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-886.
119. Rustin P, Bonnet D, Rötig A, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2004; 62: 524-525.
120. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2009; 15(Suppl. 3): S189-194.
121. Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010; 25: 1670-1674.
122. Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 2011; 26: 2316-2323.
123. Schapira AH. Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2012; 16: 965-973.
124. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007; 64: 938-944.
125. Müller T, Büttner T, Gholipour AF, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003; 341: 201-204.
126. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23: 942-949.
127. Ries V, Oertel WH, Höglinger GU. Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy. J Mol Neurosci 2011; 45: 684-689.
128. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373-418.
129. Caso G, Kelly P, McNurlan MA, et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99: 1409-1412.
130. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007; 100: 1400-1403.
131. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007; 7(Suppl.): S168-174.
132. Stemer AB, Huisa BN, Zivin JA. The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of NEST-1 and NEST-2. Curr Cardiol Rep 2010; 12: 29-33.